Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review

Background: The aim of this review was to evaluate the efficacy and safety of antibiotic agents in children with COVID-19, as well as to introduce the present situation of antibiotics use and bacterial coinfections in COVID-19 patients Methods: We searched Cochrane library, Medline, Embase, Web of Science, CBM, Wanfang Data and CNKI from their inception to March 31, 2020 In addition, we searched related studies on COVID-19 published before March 31, 2020 through Google Scholar We evaluated the risk of bias of included studies, and synthesized the results using a qualitative synthesis Results: Six studies met our inclusion criteria Five studies on SARS showed an overall risk of death of 7 2% to 20 0% One study of SARS patients who used macrolides, quinolones or beta lactamases showed that the mean duration of hospital stay was 14 2, 13 8 and 16 2 days, respectively, and their average duration of fever was 14 3, 14 0 and 16 2 days, respectively One cohort study on MERS indicated that macrolide therapy was not associated with a significant reduction in 90-day mortality (adjusted OR 0 84, 95% CI: 0 47-1 51, P=0 56) and improvement in MERS-CoV RNA clearance (adjusted HR 0 88, 95% CI: 0 47-1 64, P=0 68) According to the findings of 33 studies, the proportion of antibiotics use ranged from 19 4% to 100 0% in children and 13 2% to 100 0% in adults, despite the lack of etiological evidence The most commonly used antibiotics in adults were quinolones, cephalosporins and macrolides and in children meropenem and linezolid Conclusions: The benefits of antibiotic agents for adults with SARS or MERS were questionable in the absence of bacterial coinfections There is no evidence to support the use of antibiotic agents for children with COVID-19 in the absence of bacterial coinfection